Sun Pharma Subsidiaries Settle US Antitrust Litigation

Parties Involved

• Sun Pharmaceutical Industries Limited ("Sun Pharma") as the parent company
• Subsidiaries: Sun Pharmaceutical Industries, Inc. ("SPII"), Taro Pharmaceutical Industries Ltd. ("Taro Ltd."), and Taro Pharmaceuticals U.S.A., Inc. ("Taro USA")
• Plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation (name not disclosed)

Legal Context

The settlement agreement pertains to litigation pending in the Eastern District of Pennsylvania, United States.

Settlement Terms

• Settlement amount: Confidential (not disclosed)
• Settlement provides full release of all claims asserted against the subsidiaries
• Release extends to all current and former parents, affiliates, predecessors and successors of the subsidiaries
• Release also covers current and former directors, officers, employees and representatives of the subsidiaries
• Other terms of the settlement remain confidential

Legal Position

The settlement agreement is entered into without admission of any wrongdoing in the Action.

Financial Impact

Settlement payment will be made by the subsidiaries. Exact financial impact not quantified in the disclosure due to confidential nature of settlement amount.